| Literature DB >> 16344537 |
K L Ferrante1, J Shefner, H Zhang, R Betensky, M O'Brien, H Yu, M Fantasia, J Taft, M F Beal, B Traynor, K Newhall, P Donofrio, J Caress, C Ashburn, B Freiberg, C O'Neill, C Paladenech, T Walker, A Pestronk, B Abrams, J Florence, R Renna, J Schierbecker, B Malkus, M Cudkowicz.
Abstract
An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.Entities:
Mesh：
Substances：
Year: 2005 PMID： 16344537 DOI： 10.1212/01.wnl.0000187070.35365.d7
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910